Skip to main content
NCBI home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 1991 Dec;16(5):262–266.

Effect of bromocriptine in patients with apomorphine-responsive erectile impotence: an open study.

S Lal 1, M E Kiely 1, J X Thavundayil 1, J D Stewart 1, P Assalian 1, C F Ackman 1
PMCID: PMC1188363  PMID: 1797100

Abstract

An open pilot study was undertaken to investigate the therapeutic effect of the dopaminergic agent, bromocriptine (BC), in impotent patients who developed an erectile response to the dopamine receptor agonist, apomorphine. Eight out of 17 patients reported improvement in ability to obtain an erection; five of these 8 subjects were able to achieve penetration. The optimum dose of BC was 2.5 - 11.25 mg/day. A double-blind placebo-controlled study is merited.

Full text

PDF
262

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrosi B., Bara R., Travaglini P., Weber G., Beck Peccoz P., Rondena M., Elli R., Faglia G. Study of the effects of bromocriptine on sexual impotence. Clin Endocrinol (Oxf) 1977 Nov;7(5):417–421. doi: 10.1111/j.1365-2265.1977.tb03351.x. [DOI] [PubMed] [Google Scholar]
  2. Argiolas A., Melis M. R., Vargiu L., Gessa G. L. d(CH2)5Tyr(Me)-[Orn8]vasotocin, a potent oxytocin antagonist, antagonizes penile erection and yawning induced by oxytocin and apomorphine, but not by ACTH-(1-24). Eur J Pharmacol. 1987 Feb 10;134(2):221–224. doi: 10.1016/0014-2999(87)90168-3. [DOI] [PubMed] [Google Scholar]
  3. Benkert O. Pharmacotherpay of sexual impotence in the male. Mod Probl Pharmacopsychiatry. 1980;15:158–173. doi: 10.1159/000402342. [DOI] [PubMed] [Google Scholar]
  4. Bommer J., Ritz E., del Pozo E., Bommer G. Improved sexual function in male haemodialysis patients on bromocriptine. Lancet. 1979 Sep 8;2(8141):496–497. doi: 10.1016/s0140-6736(79)91553-8. [DOI] [PubMed] [Google Scholar]
  5. Brindley G. S. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry. 1983 Oct;143:332–337. doi: 10.1192/bjp.143.4.332. [DOI] [PubMed] [Google Scholar]
  6. Cleeves L., Findley L. J. Bromocriptine induced impotence in Parkinson's disease. Br Med J (Clin Res Ed) 1987 Aug 8;295(6594):367–368. doi: 10.1136/bmj.295.6594.367-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cooper A. J. Bromocriptine in impotence. Lancet. 1977 Sep 10;2(8037):567–567. doi: 10.1016/s0140-6736(77)90715-2. [DOI] [PubMed] [Google Scholar]
  8. Danjou P., Alexandre L., Warot D., Lacomblez L., Puech A. J. Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol. 1988 Dec;26(6):733–739. doi: 10.1111/j.1365-2125.1988.tb05312.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldstein M., Lew J. Y., Nakamura S., Battista A. F., Lieberman A., Fuxe K. Dopaminephilic properties of ergot alkaloids. Fed Proc. 1978 Jun;37(8):2202–2206. [PubMed] [Google Scholar]
  10. Gower A. J., Berendsen H. G., Princen M. M., Broekkamp C. L. The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity. Eur J Pharmacol. 1984 Aug 3;103(1-2):81–89. doi: 10.1016/0014-2999(84)90192-4. [DOI] [PubMed] [Google Scholar]
  11. Holmgren B., Urbá-Holmgren R., Trucios N., Zermeño M., Eguíbar J. R. Association of spontaneous and dopaminergic-induced yawning and penile erections in the rat. Pharmacol Biochem Behav. 1985 Jan;22(1):31–35. doi: 10.1016/0091-3057(85)90481-2. [DOI] [PubMed] [Google Scholar]
  12. Lal S., Ackman D., Thavundayil J. X., Kiely M. E., Etienne P. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry. 1984;8(4-6):695–699. doi: 10.1016/0278-5846(84)90040-x. [DOI] [PubMed] [Google Scholar]
  13. Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):117–164. doi: 10.1016/0278-5846(88)90033-4. [DOI] [PubMed] [Google Scholar]
  14. Lal S., De la Vega C. E. Apomorphine and psychopathology. J Neurol Neurosurg Psychiatry. 1975 Jul;38(7):722–726. doi: 10.1136/jnnp.38.7.722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lal S., Guyda H., Bikadoroff S. Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men. J Clin Endocrinol Metab. 1977 Apr;44(4):766–770. doi: 10.1210/jcem-44-4-766. [DOI] [PubMed] [Google Scholar]
  16. Lal S., Laryea E., Thavundayil J. X., Nair N. P., Negrete J., Ackman D., Blundell P., Gardiner R. J. Apomorphine-induced penile tumescence in impotent patients--preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(2-3):235–242. doi: 10.1016/0278-5846(87)90066-2. [DOI] [PubMed] [Google Scholar]
  17. Lal S., Rios O., Thavundayil J. X. Treatment of impotence with trazodone: a case report. J Urol. 1990 Apr;143(4):819–820. doi: 10.1016/s0022-5347(17)40107-8. [DOI] [PubMed] [Google Scholar]
  18. Lal S., Tesfaye Y., Thavundayil J. X., Thompson T. R., Kiely M. E., Nair N. P., Grassino A., Dubrovsky B. Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(3-4):329–339. doi: 10.1016/0278-5846(89)90122-x. [DOI] [PubMed] [Google Scholar]
  19. March C. M. Bromocriptine in the treatment of hypogonadism and male impotence. Drugs. 1979 May;17(5):349–358. doi: 10.2165/00003495-197917050-00004. [DOI] [PubMed] [Google Scholar]
  20. Muir J. W., Besser G. M., Edwards C. R., Rees L. H., Cattell W. R., Ackrill P., Baker L. R. Bromocriptine improves reduced libido and potency in men receiving maintenance hemodialysis. Clin Nephrol. 1983 Dec;20(6):308–314. [PubMed] [Google Scholar]
  21. Nair N. P., Lal S., Iskandar H. I., Etienne P., Wood P. L., Guyda H. Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion. Brain Res Bull. 1982 Jun;8(6):587–591. doi: 10.1016/0361-9230(82)90085-5. [DOI] [PubMed] [Google Scholar]
  22. Ottesen B., Wagner G., Virag R., Fahrenkrug J. Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br Med J (Clin Res Ed) 1984 Jan 7;288(6410):9–11. doi: 10.1136/bmj.288.6410.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Roehrich H., Dackis C. A., Gold M. S. Bromocriptine. Med Res Rev. 1987 Apr-Jun;7(2):243–269. doi: 10.1002/med.2610070206. [DOI] [PubMed] [Google Scholar]
  24. Schlatter E. K., Lal S. Treatment of alcoholism with Dent's oral apomorphine method. Q J Stud Alcohol. 1972 Jun;33(2):430–436. [PubMed] [Google Scholar]
  25. Segraves R. T., Bari M., Segraves K., Spirnak P. Effect of apomorphine on penile tumescence in men with psychogenic impotence. J Urol. 1991 Jun;145(6):1174–1175. doi: 10.1016/s0022-5347(17)38565-8. [DOI] [PubMed] [Google Scholar]
  26. Thorner M. O., McNeilly A. S., Hagan C., Besser G. M. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J. 1974 May 25;2(5916):419–422. doi: 10.1136/bmj.2.5916.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Waddington J. L. Behavioural correlates of the action of selective D-1 dopamine receptor antagonists. Impact of SCH 23390 and SKF 83566, and functionally interactive D-1:D-2 receptor systems. Biochem Pharmacol. 1986 Nov 1;35(21):3661–3667. doi: 10.1016/0006-2952(86)90649-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Science Publishing

RESOURCES